British Society for Sexual Medicine Guidelines on Adult Testosterone Deficiency, with Statements for UK Practice
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Background: Testosterone deficiency (TD) is an increasingly common problem with significant health implications, but its diagnosis and management can be challenging. Aim: To review the available literature on TD and provide evidence-based statements for UK clinical practice. Methods: Evidence was derived from Medline, EMBASE, and Cochrane searches on hypogonadism, testosterone (T) therapy, and cardiovascular safety from May 2005 to May 2015. Further searches continued until May 2017. Outcomes: To provide a guideline on diagnosing and managing TD, with levels of evidence and grades of recommendation, based on a critical review of the literature and consensus of the British Society of Sexual Medicine panel. Results: 25 statements are provided, relating to 5 key areas: screening, diagnosis, initiating T therapy, benefits and risks of T therapy, and follow-up. 7 statements are supported by level 1, 8 by level 2, 5 by level 3, and 5 by level 4 evidence. Clinical Implications: To help guide UK practitioners on effectively diagnosing and managing primary and age-related TD. Strengths and Limitations: A large amount of literature was carefully sourced and reviewed, presenting the best evidence available at the time. However, some statements provided are based on poor-quality evidence. This is a rapidly evolving area of research and recommendations are subject to change. Guidelines can never replace clinical expertise when making treatment decisions for individual patients, but rather help to focus decisions and take personal values and preferences and individual circumstances into account. Many issues remain controversial, but in the meantime, clinicians need to manage patient needs and clinical expectations armed with the best clinical evidence and the multidisciplinary expert opinion available. Conclusion: Improving the diagnosis and management of TD in adult men should provide somatic, sexual, and psychological benefits and subsequent improvements in quality of life.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum
Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6079 · Cited by 3,824 · cited 2×
“In obese men, the free androgen index, calculated as TT/SHBG 100, is used by some laboratories but we recommend the calculated FT derived from SHBG and albumin through the equation of Vermeulen et al.(121) An online FT calculator and downloadable app, sponsored by the Primary Care Testosterone Advisory Group, can be f…”
MethodBhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954 · cited 3×
“Combined primary and secondary TD, sometimes known as mixed TD, is associated with low T levels, impaired spermatogenesis, and variable FSH and LH levels, depending on whether primary or secondary testicular failure predominates.(22) Combined primary and secondary TD occurs with certain conditions such as sickle cell…”
BackgroundInfluentialGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Identification of late-onset hypogonadism in middle-aged and elderly men
Wu, F. C. W., Tajar, A., Beynon, J. M., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F. F., Forti, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911101 · Cited by 1,544 · cited 1×
“22 nmol/L]).(8) However, 75% of men maintained normal T levels into old age, suggesting that TD is not merely a function of aging.”
BackgroundAdverse Events Associated with Testosterone Administration
Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000485 · Cited by 1,494
The Decline of Androgen Levels in Elderly Men and Its Clinical and Therapeutic Implications
Kaufman, J. M., & Vermeulen, A. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0013 · Cited by 1,079
Vigen, R. (2013) · JAMA · doi:10.1001/jama.2013.280386 · Cited by 1,003
Testosterone dose-response relationships in healthy young men
Bhasin, S., Woodhouse, L., Casaburi, R., Singh, A. B., Bhasin, D., Berman, N., Chen, X., Yarasheski, K. E., Magliano, L., Dzekov, C., et al. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.6.e1172 · Cited by 967
Effects of Testosterone Treatment in Older Men
Snyder, P. J., Bhasin, S., Cunningham, G. R., Matsumoto, A. M., Stephens-Shields, A. J., Cauley, J. A., Gill, T. M., Barrett-Connor, E., Swerdloff, R. S., Wang, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506119 · Cited by 890
Prevalence of hypogonadism in males aged at least 45 years: the HIM study
MULLIGAN, T., FRICK, M. F., ZURAW, Q. C., STEMHAGEN, A., & MCWHIRTER, C. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.00992.x · Cited by 767 · cited 1×
“20 for lower urinary tract symptoms related to benign prostatic hyperplasia.(32) Significant TD is associated with an increased risk of chronic anemia and osteoporosis.”
BackgroundIncreased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men
Finkle, W. D., Greenland, S., Ridgeway, G. K., Adams, J. L., Frasco, M. A., Cook, M. B., Fraumeni, J. F., & Hoover, R. N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085805 · Cited by 735 · cited 3×
“A study analyzing prescribing data in men treated with T therapy, without records of blood results or symptoms, defined non-fatal coronary events as themajor end point, assessed in the 12 months before and 3 months after therapy.(77) However, the benefits of T therapy take longer than this to appear and other studies…”
BackgroundInfluentialCalof, O. M., Singh, A. B., Lee, M. L., Kenny, A. M., Urban, R. J., Tenover, J. L., & Bhasin, S. (2005) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/60.11.1451 · Cited by 728 · cited 1×
“0 ng/mL, or urinary symptom scores between those receiving T therapy and those receiving placebo.(101)”
BackgroundEndogenous Testosterone and Mortality in Men: A Systematic Review and Meta-Analysis
Araujo, A. B., Dixon, J. M., Suarez, E. A., Murad, M. H., Guey, L. T., & Wittert, G. A. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1137 · Cited by 671 · cited 1×
“However, most of these studies had issues with cohort selection and choice.(63)”
BackgroundSrinivas-Shankar, U., Roberts, S. A., Connolly, M. J., O'Connell, M. D. L., Adams, J. E., Oldham, J. A., & Wu, F. C. W. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1251 · Cited by 629 · cited 1×
“The clinical and physiologic responses to T therapy, particularly the benefits of increased muscle mass and strength,(54) might be more clinically and economically significant in older men, because decreased muscle mass and lower limb strength are strongly related to frailty and an increased rate of falls.(131)”
BackgroundTajar, A., Forti, G., O'Neill, T. W., Lee, D. M., Silman, A. J., Finn, J. D., Bartfai, G., Boonen, S., Casanueva, F. F., Giwercman, A., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1796 · Cited by 604
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Association of Specific Symptoms and Metabolic Risks with Serum Testosterone in Older Men
Zitzmann, M., Faber, S., & Nieschlag, E. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0401 · Cited by 552
Jones, T. H., Arver, S., Behre, H. M., Buvat, J., Meuleman, E., Moncada, I., Morales, A. M., Volterrani, M., Yellowlees, A., Howell, J. D., et al. (2011) · Diabetes Care · doi:10.2337/dc10-1233 · Cited by 548
Self-citationEmmelot-Vonk, M. H., Verhaar, H. J. J., Nakhai Pour, H. R., Aleman, A., Lock, T. M. T. W., Bosch, J. L. H. R., Grobbee, D. E., & van der Schouw, Y. T. (2008) · JAMA · doi:10.1001/jama.2007.51 · Cited by 518
Brambilla, D. J., Matsumoto, A. M., Araujo, A. B., & McKinlay, J. B. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1902 · Cited by 448 · cited 1×
“Although diurnal variation is substantially blunted inoldermen,(26) itmight still be evident, even in the elderly, supporting the recommendation of restricting T measurement to the morning hours for all age groups.(117) Serum T should be measured from 7 to 11 AM (LoE 1⁄4 2a, Grade 1⁄4 A) on at least 2 occasions with a…”
MethodCamacho, E. M., Huhtaniemi, I. T., O'Neill, T. W., Finn, J. D., Pye, S. R., Lee, D. M., Tajar, A., Bartfai, G., Boonen, S., Casanueva, F. F., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-12-0890 · Cited by 392
Testosterone and Cardiovascular Disease
Kloner, R. A., Carson, C., Dobs, A., Kopecky, S., & Mohler, E. R. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.12.005 · Cited by 371
Snyder, P. J., Kopperdahl, D. L., Stephens-Shields, A. J., Ellenberg, S. S., Cauley, J. A., Ensrud, K. E., Lewis, C. E., Barrett-Connor, E., Schwartz, A. V., Lee, D. C., et al. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.9539 · Cited by 363 · cited 1×
“Larger and longer trials are required to determine whether this treatment also lowers fracture risk.(57) Earlier evidence had shown that T therapy consistently improved bone mineral density in the lumbar spine but was not associated with significant improvements in hip scores.”
BackgroundPope, H. G., Cohane, G. H., Kanayama, G., Siegel, A. J., & Hudson, J. I. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.105 · Cited by 341
Liu, P. Y., Swerdloff, R. S., Christenson, P. D., Handelsman, D. J., & Wang, C. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68614-5 · Cited by 272
Grossmann, M., & Matsumoto, A. M. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3580 · Cited by 246
Association of Testosterone Levels With Anemia in Older Men: A Controlled Clinical Trial
Roy, C. N., Snyder, P. J., Stephens-Shields, A. J., Artz, A. S., Bhasin, S., Cohen, H. J., Farrar, J. T., Gill, T. M., Zeldow, B., Cella, D., et al. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.9540 · Cited by 239
Resnick, S. M., Matsumoto, A. M., Stephens-Shields, A. J., Ellenberg, S. S., Gill, T. M., Shumaker, S. A., Pleasants, D. D., Barrett-Connor, E., Bhasin, S., Cauley, J. A., et al. (2017) · JAMA · doi:10.1001/jama.2016.21044 · Cited by 220 · cited 1×
“The Anaemia Trial(55) found that T therapy significantly increased hemoglobin levels in men with anemia from unexplained or known causes,(59) whereas the Cognitive Function Trial(55) found no effect on memory or other cognitive function.(60) Several meta-analyses of RCTs, notably by Corona et al(61) in 2017, concluded…”
ResultCorona, G., Giagulli, V. A., Maseroli, E., Vignozzi, L., Aversa, A., Zitzmann, M., Saad, F., Mannucci, E., & Maggi, M. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-0262 · Cited by 217 · cited 1×
“In a meta-analysis of 59 RCTs involving 5,078 subjects, T therapy was not associated with any significant changes in body weight, BMI, or waist circumference, but it consistently improved lean muscle and decreased fat mass.(54)”
Khera, M., Adaikan, G., Buvat, J., Carrier, S., El-Meliegy, A., Hatzimouratidis, K., McCullough, A., Morgentaler, A., Torres, L. O., & Salonia, A. (2016) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2016.10.009 · Cited by 177
Corona, G., Rastrelli, G., & Maggi, M. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.05.002 · Cited by 177 · cited 1×
“Another meta-analysis, published the same year, concluded that T therapy was not associated with increased risk, and in certain cohorts there was evidence of fewer events, especially in men with cardiometabolic disease.(93)”
Antonio, L., Wu, F. C. W., O'Neill, T. W., Pye, S. R., Ahern, T. B., Laurent, M. R., Huhtaniemi, I. T., Lean, M. E. J., Keevil, B. G., Rastrelli, G., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-4106 · Cited by 174
Correlates of low testosterone and symptomatic androgen deficiency in a population-based sample
Hall, S. A., Esche, G. R., Araujo, A. B., Travison, T. G., Clark, R. V., Williams, R. E., & McKinlay, J. B. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0021 · Cited by 167
Saad, F., Aversa, A., M. Isidori, A., & J. Gooren, L. (2012) · Current Diabetes Reviews · doi:10.2174/157339912799424573 · Cited by 148
Corona, G., Mannucci, E., Petrone, L., Balercia, G., Fisher, A. D., Chiarini, V., Forti, G., & Maggi, M. (2006) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2006.00262.x · Cited by 130
Hypogonadism and metabolic syndrome.
(2011) · PubMed · doi:10.3275/7806 · Cited by 125
Ng Tang Fui, M., Prendergast, L. A., Dupuis, P., Raval, M., Strauss, B. J., Zajac, J. D., & Grossmann, M. (2016) · BMC Medicine · doi:10.1186/s12916-016-0700-9 · Cited by 124
Testosterone suppression in opioid users: A systematic review and meta-analysis
Bawor, M., Bami, H., Dennis, B. B., Plater, C., Worster, A., Varenbut, M., Daiter, J., Marsh, D. C., Steiner, M., Anglin, R., et al. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.01.038 · Cited by 123
Morris, P., Malkin, C., Channer, K., & Jones, T. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1510241 · Cited by 122 · cited 1×
“The free androgen index is not as reliable as FT or bioavailable T.(122)”
Self-citationAversa, A., Bruzziches, R., Francomano, D., Greco, E. A., Fornari, R., Luigi, L. D., Lenzi, A., & Migliaccio, S. (2012) · The Aging Male · doi:10.3109/13685538.2011.631230 · Cited by 108
O'Connell, M. D. L., Roberts, S. A., Srinivas-Shankar, U., Tajar, A., Connolly, M. J., Adams, J. E., Oldham, J. A., & Wu, F. C. W. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1167 · Cited by 98 · cited 1×
“For treatment duration, in 2 RCTs involving 447 men 45 to 90 years old, cessation of T therapy resulted in relapse and reversal of benefits within 6 months, so it is likely to be required life long.(47,135)”
MethodNg Tang Fui, M., Hoermann, R., Prendergast, L. A., Zajac, J. D., & Grossmann, M. (2017) · International Journal of Obesity · doi:10.1038/ijo.2016.242 · Cited by 40
Testosterone administration in older men
Matsumoto, A. M. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.02.011 · Cited by 32
Cited by
Agarwal, A., Baskaran, S., Parekh, N., Cho, C.-L., Henkel, R., Vij, S., Arafa, M., Panner Selvam, M. K., & Shah, R. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32667-2 · Cited by 1,284
Paediatric and adult-onset male hypogonadism
Salonia, A., Rastrelli, G., Hackett, G., Seminara, S. B., Huhtaniemi, I. T., Rey, R. A., Hellstrom, W. J. G., Palmert, M. R., Corona, G., Dohle, G. R., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0087-y · Cited by 286
Self-citationMale Obesity-related Secondary Hypogonadism – Pathophysiology, Clinical Implications and Management
Fernandez, C. J., Department of Endocrinology & Metabolism, P. H., Chacko, E. C., Department of Endocrinology, J. G. H., Pappachan, J. M., & Department of Endocrinology & Metabolism, L. T. H. N. F. T. (2019) · European Endocrinology · doi:10.17925/ee.2019.15.2.83 · Cited by 145
“Diagnostic recommendations based on British Society for Sexual Medicine guidelines are shown in Table 1.(50)”
MethodNovel Therapy for Male Hypogonadism
Carrasquillo, R., Chu, K., & Ramasamy, R. (2018) · Current Urology Reports · doi:10.1007/s11934-018-0816-x · Cited by 31
Ageing male (part I): Pathophysiology and diagnosis of functional hypogonadism
Huhtaniemi, I. T., & Wu, F. C. W. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101622 · Cited by 31
Metadata
- Authors
- Hackett, G., Kirby, M., Edwards, D., Jones, T. H., Wylie, K., Ossei-Gerning, N., David, J., & Muneer, A.
- Venue
- The Journal of Sexual Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-12-01
- Volume
- 14
- Issue
- 12
- Pages
- 1504-1523
- ISSN
- 1743-6095 (ISSN-L)
- 1743-6109
- OpenAlex
- W2774513630
- Cited by
- 143
- References
- 43
- FWCI
- 9.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.